Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 81 for your search:
Drug:
tacrolimus
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Approved-not yet active
Age:
18 to 50
Sponsor:
Other
Protocol IDs:
IIS-002-09
, NCT00922129
2.
TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients
Phase:
Phase III
Type:
Supportive care
Status:
Active
Age:
18 to 80
Sponsor:
Other
Protocol IDs:
2003.333
, NCT00133887
3.
Phase III Randomized Study of Graft-Versus-Host Disease Prophylaxis Comprising Tacrolimus and Methotrexate With or Without Sirolimus in Pediatric Patients With Intermediate-Risk or High-Risk Acute Lymphoblastic Leukemia in Second Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
1 to under 22 at first relapse
Sponsor:
NCI
Protocol IDs:
COG-ASCT0431
, ASCT0431, COG-PBMTC-ONCO51, NCT00382109
4.
Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
12 to 65
Sponsor:
Other
Protocol IDs:
PROGAST
, NCT00180089
5.
Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria
Phase:
Phase III
Type:
Supportive care
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
ZSH-LCI-FJ-0002
, NCT00554125
6.
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
2 to 55
Sponsor:
NCI, NHLBI
Protocol IDs:
385
, BMT CTN 0402, U01 HL069294-05, NCT00406393
7.
Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 72
Sponsor:
NCI, Other
Protocol IDs:
09-073
, NCT00928018
8.
Bortezomib Plus Tacrolimus and Methotrexate to Prevent GVHD After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
06-065
, X05175, NCT00369226
9.
Phase I/II Study of Cytoreduction Therapy Comprising Clofarabine, Melphalan, and Thiotepa Followed By Allogeneic Unmodified Hematopoietic Stem Cell Transplantion in Patients With High-Risk and/or Advanced Hematologic Malignancies or Other Diseases
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Under 55
Sponsor:
NCI
Protocol IDs:
MSKCC-06125
, NCT00423514
10.
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
2006-0803
, NCT00410982
11.
Phase I/II Study of Cyclophosphamide and Busulfan Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Idiopathic Myelofibrosis
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
65 and under
Sponsor:
NCI
Protocol IDs:
FHCRC-2130.00
, 6447, NCT00445744
12.
Phase I/II Study of Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Fanconi Anemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
FHCRC-2064.00
, 6294, NCT00453388
13.
Fludarabine-based Conditioning for Severe Aplastic Anemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
NCI, NHLBI
Protocol IDs:
383
, BMT CTN 0301, 5 U01 HL69294-05, NCT00326417
14.
Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
EK 92062003
, NCT00460447
15.
Phase I/II Randomized Pilot Study of Targeted Immune-Depleting Chemotherapy, Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation from an HLA-Matched Unrelated Donor, and Graft-Versus-Host Disease Prophylaxis Comprising Tacrolimus, Methotrexate, and Sirolimus Versus Alemtuzumab and Cyclosporine in Patients With High-Risk Advanced Hematologic Malignancies or Other Diseases
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 69
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0195
, 07-C-0195, NCT00520130
16.
Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
30 and under
Sponsor:
Other
Protocol IDs:
CHNY-06-532
, AAAC0918, NCT00529360
17.
Phase I/II Study of Alemtuzumab, Bulsulfan, and Cyclophosphamide Followed by HLA-Mismatched Unrelated Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
50 and under
Sponsor:
NCI
Protocol IDs:
FHCRC-1981.00
, 6508, NCT00555048
18.
Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
BCM-H-19386
, BCM-FAB, H 19386, NCT00625144
19.
Phase I/II Pilot Study of a Nonmyeloablative Conditioning Regimen Comprising Anti-CD45 Monoclonal Antibody, Alemtuzumab, Fludarabine Phosphate , and Low-Dose Total-Body Irradiation Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients With High-Risk Hematological Diseases
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 100
Sponsor:
Other
Protocol IDs:
BCM-H-12472
, H 12472, BCM-ACHE, NCT00056966
20.
Phase I/II Prospective Study of Nonmyeloablative Related Allogeneic HLA-Haploidentical Bone Marrow Transplantation Followed By Single Prophylactic Donor Lymphocyte Infusion of NK Cells in Patients With Hematological Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
FHCRC-2230.00
, 2230.00, IR-6771, NCT00789776
21.
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
2007-0772
, NCT00822770
22.
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
MC078F
, NCI-2009-01249, NCT00995059
23.
Phase II Study of Sequential Chemotherapy, Imatinib Mesylate, and Peripheral Blood Stem Cell Transplantation in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
15 to 59
Sponsor:
NCI
Protocol IDs:
CALGB-C10001
, CALGB-10001, NCT00039377
24.
Phase II Pilot Study of Induction Chemotherapy Followed By Allogeneic/Syngeneic Peripheral Blood Stem Cell Transplantation in Patients With High-Risk, Recurrent Pediatric Sarcoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
4 to 35
Sponsor:
NCI
Protocol IDs:
NCI-02-C-0259
, NCT00047372
25.
Phase II Study of Combined Immunosuppression Before and After Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation in Patients With High-Risk Hematologic Malignancies
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
FHCRC-1667.00
, NCI-H02-0098, NCT00049504
Select All on Page
1
Help with Results
